Skip to main content
Premium Trial:

Request an Annual Quote

Greenwood Genetic Center to Use FDNA Technology for Rare Disease Patient Analysis

NEW YORK (GenomeWeb) – Greenwood Genetic Center announced today that it has signed an agreement to use FDNA's Face2Gene next-generation phenotyping technology in order to gain insights into thousands of undiagnosed patients with rare diseases.

Face2Gene uses facial analysis, deep learning, and artificial intelligence to evaluate symptoms of patients with rare genetic diseases and suggest possible diagnoses based on a database of more than 10,000 rare disease syndromes.

Under the terms of the deal, GGC will use Face2Gene to analyze nearly 80,000 undiagnosed cases with the goal of generating actionable answers for these patients, identifying new syndrome-related clinical phenotypes, and making rare disease discoveries that can advance overall research. FDNA will use data from these analyses to strengthen its database of known diagnoses.

Additional terms were not disclosed.

"The GGC clinical team has already received the first insights from FDNA," Hannah Warren, a clinical genetic counselor at GGC, said in a statement. "There are dozens of high priority, undiagnosed cases that have been flagged by Face2Gene due to their statistically significant facial analysis insights. These new insights may help find a diagnosis for patients who have been searching for answers for much too long."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more